Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Mydecine Innovations Group Inc (MYCOF) Message Board

Study Finds That Sleep Deprivation Increases Serot

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 160
(Total Views: 213)
Posted On: 01/20/2022 4:45:51 PM
Avatar
Posted By: NetworkNewsWire
Study Finds That Sleep Deprivation Increases Serotonin 2AReceptor Levels in Brain

A new study conducted by researchers at the University of Arizona Health Sciences has found that sleep deprivation can cause a significant increase in serotonin 2A levels in a matter of hours in animal models.Serotonin 2A, or the 5-HT2A receptor, plays a crucial role in cognition, perception and psychosis. The receptor is extensively distributed in the brain and is responsible for the psychedelic effect of substances such as LSD and psilocybin.

Abnormal function of 5-HT2A receptors has been linked to psychiatric disorders, including schizophrenia, which explains why antipsychotic medications prescribed for the treatment of schizophrenia have been designed to target serotonin 2A receptors and help reduce symptoms of impaired cognition.

The study’s findings suggest that environmental stimuli could modify the balance in brain receptors that are controlled by antipsychotic medications for people with schizophrenia.

Schizophrenia is a mental disorder that is characterized by abnormalities in memory, thinking and perception. This disorder disrupts an individual’s memory and sleep processes as well as their cognition, causing them to experience disassociation from reality and hallucinations.

The study was led by Amelia Gallitano, who stated that the research had demonstrated that it was possible for environmental stressors to alter the levels of receptors, which played crucial roles in the brain, in several hours.Prior research has shown that receptor proteins on brain cell surfaces control the brain’s communication network. These receptors are made when a gene is turned on to produce mRNA that the cells use to create receptor proteins such as the 5-HT2A receptor.

The number of receptors created and the number present on the surface of brain cells help determine how brain cellsrespond to serotonin as well as how drugs such as antipsychotics bind to the receptor. The researchers found that the proteins produced by an early-growth response gene known as EGR3 were also required for 5-HT2A receptor expression. The primary function of EGR3 is to turn other genes on and off and bind to DNA.

The researchers discovered that stimuli caused by sleep deprivation set off EGR3 to bind to the 5-HT2A receptor gene, which caused it to relay mRNA instructionsto produce more proteins. This is what caused an increase in serotonin 2A levels present in the brain in a matter of hours.

The study’s findings improve the understanding of how the environment modifiesthe expression of brain receptors, which moderate function in the prefrontal cortex region. This region is essential for working memory and spatial reasoning. Dysfunction in the prefrontal cortex region could contribute to the cognitive deficits, which characterize schizophrenia.

The findings of this research help to broaden the scientific community’s understanding of how psychedelics work, and this in turn could open up new avenues for companies such as Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) to come up with a new class of drugs targeting mental health disorders.

NOTE TO INVESTORS: The latest news and updates relating to Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) are available in the company’s newsroom at https://ibn.fm/MYCOF

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer




(0)
(0)




Mydecine Innovations Group Inc (MYCOF) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us